TrialCancer2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Marcia S Brose et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this paperpooled ittrialcites it